A5019070324- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Endometriosis Research and Treatment
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- BRCA gene mutations in cancer
- PI3K/AKT/mTOR signaling in cancer
- Colorectal Cancer Screening and Detection
- Epigenetics and DNA Methylation
- Cancer Risks and Factors
- Genetic factors in colorectal cancer
- Cancer-related molecular mechanisms research
- Genetic Associations and Epidemiology
- Ovarian function and disorders
- Cancer Diagnosis and Treatment
- Cervical Cancer and HPV Research
- Global Cancer Incidence and Screening
- Cancer-related gene regulation
- Estrogen and related hormone effects
- HER2/EGFR in Cancer Research
- Genetic Syndromes and Imprinting
- Cancer, Lipids, and Metabolism
- Cancer Treatment and Pharmacology
- RNA modifications and cancer
- Molecular Biology Techniques and Applications
University College London
2016-2025
MRC Clinical Trials Unit at UCL
1991-2025
London Women's Clinic
2006-2023
Luton and Dunstable University Hospital NHS Foundation Trust
2023
Belfast City Hospital
2016-2021
Queen Alexandra Hospital
2021
St Mary's Hospital
2009-2021
London School of Economics and Political Science
2021
St. Mary's Hospital
2009-2021
Nottingham City Hospital
2021
Ovarian cancer has a poor prognosis, with just 40% of patients surviving 5 years. We designed this trial to establish the effect early detection by screening on ovarian mortality.
Ovarian cancer has a high case-fatality ratio, with most women not diagnosed until the disease is in its advanced stages. The United Kingdom Collaborative Trial of Cancer Screening (UKCTOCS) randomised controlled trial designed to assess effect screening on mortality. This report summarises outcome prevalence (initial) screen UKCTOCS.Between 2001 and 2005, total 202 638 post-menopausal aged 50-74 years were randomly assigned no treatment (control; n=101 359); annual CA125 (interpreted using...
BackgroundOvarian cancer continues to have a poor prognosis with the majority of women diagnosed advanced disease. Therefore, we undertook UK Collaborative Trial Ovarian Cancer Screening (UKCTOCS) determine if population screening can reduce deaths due We report on ovarian mortality after long-term follow-up in UKCTOCS.MethodsIn this randomised controlled trial, postmenopausal aged 50–74 years were recruited from 13 centres National Health Service trusts England, Wales, and Northern Ireland....
Background: The implications of different adiposity measures on cardiovascular disease etiology remain unclear. In this article, we quantify and contrast causal associations central (waist-to-hip ratio adjusted for body mass index [WHRadjBMI]) general (body [BMI]) with cardiometabolic disease. Methods: Ninety-seven independent single-nucleotide polymorphisms BMI 49 WHRadjBMI were used to conduct Mendelian randomization analyses in 14 prospective studies supplemented coronary heart (CHD) data...
Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns TILs by histotype and relation to other clinical factors.
Purpose Cancer screening strategies have commonly adopted single-biomarker thresholds to identify abnormality. We investigated the impact of serial biomarker change interpreted through a risk algorithm on cancer detection rates. Patients and Methods In United Kingdom Collaborative Trial Ovarian Screening, 46,237 women, age 50 years or older underwent incidence by using multimodal strategy (MMS) in which annual serum antigen 125 (CA-125) was with ovarian (ROCA). Women were triaged ROCA:...
Purpose To establish the performance of screening with serum cancer antigen 125 (CA-125), interpreted using risk ovarian algorithm (ROCA), and transvaginal sonography (TVS) for women at high (OC) or fallopian tube (FTC). Patients Methods Women whose estimated lifetime OC/FTC was ≥ 10% were recruited 42 centers in United Kingdom underwent ROCA every 4 months. TVS occurred annually if results normal within 2 months an abnormal result. Risk-reducing salpingo-oophorectomy (RRSO) encouraged...
Loss of heterozygosity and mutations in the PTEN (MMAC1) tumor suppressor gene are frequent endometrial carcinoma. Promoter hypermethylation has recently been identified as an alternative mechanism inactivation cancer, but its importance carcinoma is unknown. The purpose our study was to assess frequency promoter methylation determine correlation with clinicopathologic variables a prospective population-based series carcinomas complete follow-up. Presence seen 26 138 patients (19%)....
Abstract Purpose: In the brain, tumors may grow without inducing angiogenesis, via co-option of dense pre-existent capillary bed. The purpose this study was to investigate how phenomenon influences outcome antiangiogenic therapy. Experimental Design: Mice carrying brain metastases human, highly angiogenic melanoma cell line Mel57-VEGF-A were either or not treated with different dosages ZD6474, a vascular endothelial growth factor (VEGF) receptor 2 tyrosine kinase inhibitor additional...
The increase in the worldwide incidence of endometrial cancer relates to rising obesity, falling fertility, and ageing population. Transvaginal ultrasound (TVS) is a possible screening test, but there have been no large-scale studies. We report performance TVS large cohort.We did nested case-control study postmenopausal women who underwent United Kingdom Collaborative Trial Ovarian Cancer Screening (UKCTOCS) following recruitment between April 17, 2001, Sept 29, 2005. Endometrial thickness...
Objective To describe the factors that contributed to successful recruitment of more than 200 000 women UK Collaborative Trial Ovarian Cancer Screening, one largest ever randomised controlled trials. Design Descriptive study. Setting 13 NHS trusts in England, Wales, and Northern Ireland. Participants Postmenopausal aged 50-74; exclusion criteria included ovarian malignancy, bilateral oophorectomy, increased risk familial cancer, active non-ovarian participation other cancer screening Main...
Despite a myriad of attempts in the last three decades to diagnose ovarian cancer (OC) earlier, this clinical aim still remains significant challenge. Aberrant methylation patterns linked CpGs analyzed DNA fragments shed by cancers into bloodstream (i.e. cell-free DNA) can provide highly specific signals indicating presence. We 699 cancerous and non-cancerous tissues using array or reduced representation bisulfite sequencing discover most OC patterns. A three-DNA-methylation-serum-marker...
Please cite this paper as: Hunter M, Gentry‐Maharaj A, Ryan Burnell Lanceley Fraser L, Jacobs I, Menon U. Prevalence, frequency and problem rating of hot flushes persist in older postmenopausal women: impact age, body mass index, hysterectomy, hormone therapy use, lifestyle mood a cross‐sectional cohort study 10 418 British women aged 54–65. BJOG 2012;119:40–50. Objective Hot night sweats (HFs/NSs) are the main menopausal symptoms, but few studies have been adequately powered to examine...
Blood-borne biomarkers for early detection of colorectal cancer (CRC) could markedly increase screening uptake. The aim this study was to evaluate serum carcinoembryonic antigen (CEA), CYFRA21-1 and CA125 the CRC in an asymptomatic cohort.This nested case-control within UKCTOCS used 381 serial samples from 40 women subsequently diagnosed with CRC, 20 benign disease matched non-cancer controls three four per subject taken annually up 4 years before diagnosis. CEA, were measured using...
Breast cancer is a leading cause of morbidity and mortality worldwide. Although mammography screening available, there an ongoing interest in improved early detection prognosis. Herein, we have analysed combination serological biomarkers case-control cohort sera taken before diagnosis.This nested study within the UK Collaborative Trial Ovarian Cancer Screening (UKCTOCS) used serum samples from 239 women who subsequently developed breast matched cancer-free controls. Sera were screened by...
Abstract Background Ovarian cancer has a poor survival rate due to late diagnosis and improved methods are needed for its early detection. Our primary objective was identify incorporate additional biomarkers into longitudinal models improve on the performance of CA125 as first-line screening test ovarian cancer. Methods This case–control study nested within UKCTOCS used 490 serial serum samples from 49 women later diagnosed with 31 control who were cancer-free. Proteomics-based biomarker...
In UKCTOCS, there was a decrease in the diagnosis of advanced stage tubo-ovarian cancer but no reduction deaths multimodal screening group compared with group. Therefore, we did exploratory analyses patients high-grade serous ovarian to understand reason for discrepancy.
Objectives: The negative publicity about menopausal hormone therapy (MHT) has led to increased use of complementary and alternative medicines (CAM) non-pharmacological interventions (NPI) for symptom relief. We report on the prevalence predictors CAM/NPI among UK postmenopausal women.Method: Postmenopausal women aged 50–74 years were invited participate in Collaborative Trial Ovarian Cancer Screening (UKCTOCS). A total 202 638 recruited completed a baseline questionnaire. Of these, 136 020...
There are widespread efforts to increase symptom awareness of 'pelvic/abdominal pain, increased abdominal size/bloating, difficulty eating/feeling full and urinary frequency/urgency' in an attempt diagnose ovarian cancer earlier. Long-term survival women with these symptoms adjusted for known prognostic factors is yet be determined. This study explored the association symptoms, routes interval diagnosis long-term a population-based cohort postmenopausal diagnosed invasive epithelial...
Epithelial tubo-ovarian cancer (EOC) has high mortality partly due to late diagnosis. Prevention is available but may be associated with adverse effects. A multifactorial risk model based on known genetic and epidemiological factors (RFs) for EOC can help identify women at higher who could benefit from targeted screening prevention.
Abstract Genetic and non-genetic factors contribute to breast cancer development. An epigenome-based signature capturing these components in easily accessible samples could identify women at risk. Here, we analyse the DNA methylome 2,818 cervical, 357 227 matched buccal blood respectively, 42 tissue from with without cancer. Utilising cervical liquid-based cytology samples, develop methylation-based Women’s risk IDentification for Breast Cancer index (WID-BC-index) that identifies an AUROC...